Advancing early detection of organ damage and cardiovascular risk prevention: the Suzhou cardiometabolic health study protocol - exploring the role of oral microbiome and metabolic profiling in risk stratification

被引：0

作者：

Zhu, Mengmeng ^{[1
,2
]}

Li, Yiwen ^{[3
]}

Wang, Wenting ^{[1
]}

Liu, Longkun ^{[1
]}

Liu, Wenwu ^{[2
]}

Yu, Jiayu ^{[2
]}

Xu, Qian ^{[1
]}

Cui, Jing ^{[1
]}

Liu, Yanfei ^{[1
]}

Chen, Keji ^{[1
]}

Liu, Yue ^{[1
,2
]}

机构：

[1] China Acad Chinese Med Sci, Natl Clin Res Ctr Cardiovasc Dis Tradit Chinese Me, Xiyuan Hosp, Beijing, Peoples R China

[2] China Acad Chinese Med Sci, Suzhou Hosp Tradit Chinese Med, Xiyuan Hosp, Cardiovasc Dis Ctr, Suzhou, Jiangsu, Peoples R China

[3] China Acad Chinese Med Sci, Expt Res Ctr, Beijing Key Lab Tradit Chinese Med Basic Res Preve, Beijing, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2025年 / 16卷

关键词：

cardiovascular disease; metabolic risk factors; subclinical target organ damage; oral microbiota; risk stratification; GLOBAL BURDEN; GUIDELINES; DIET;

D O I：

10.3389/fendo.2025.1522756

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Cardiovascular Disease (CVD) is the leading cause of global mortality, with its incidence rate rising year by year due to the prevalence of metabolic diseases. Existing primary and secondary prevention strategies for cardiovascular disease have limitations in identifying some high-risk groups, and 1.5-level prevention aims to achieve more precise intervention by early identification of subclinical target organ damage. This study introduces oral (tongue coating) microbiota as metabolic markers for the first time, in combination with multiple metabolic factors, to explore their potential in assessing subclinical target organ damage and optimizing cardiovascular risk stratification, in order to provide a new path for the early identification and intervention of CVD. Methods This study is a prospective cohort study aimed at assessing the association between tongue coating microbiota characteristics and multiple metabolic factors with subclinical target organ damage, and identifying high-risk groups suitable for cardiovascular 1.5-level prevention. The study will be conducted in Suzhou City, Jiangsu Province, China, planning to include 5000-6000 eligible subjects, with inclusion criteria of age >= 18 years, excluding individuals with a history of CVD and other serious diseases. Baseline assessment includes demographic information, lifestyle (including dietary patterns), medical history, physical examination, and collection of tongue coating microbiota samples. Subjects will be followed up every 2 years, with the primary outcome being the first occurrence of coronary heart disease and stroke, and the secondary outcome being subclinical target organ damage. Discussion This study focuses on cardiovascular 1.5-level prevention strategy, combining metabolic factors with tongue coating microbiota characteristics, aiming to optimize the risk assessment system for subclinical target organ damage. This approach can not only fill the gap in traditional risk assessment but also provide new ideas for the early identification and intervention of CVD. In the future, the feasibility and effectiveness of this strategy will be verified through multicenter studies, and it is expected to be promoted to a wider medical system, significantly improving the health management level of high-risk groups for CVD. Trial registration number http://itmctr.ccebtcm.org.cn, identifier ITMCTR2024000616.

引用

页数：10

共 44 条

[1] Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Et al., Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study, J Am Coll Cardiol, 76, 25, (2020)
[2] Chew N.W.S., Ng C.H., Tan D.J.H., Kong G., Lin C., Chin Y.H., Et al., The global burden of metabolic disease: Data from 2000 to 2019, Cell Metab, 35, pp. 414-428.e3, (2023)
[3] Saxon D.R., Reiter-Brennan C., Blaha M.J., Eckel R.H., Cardiometabolic medicine: development of a new subspecialty, J Clin Endocrinol Metab, 105, (2020)
[4] Govindarajan G., Whaley-Connell A., Mugo M., Stump C., Sowers J.R., The cardiometabolic syndrome as a cardiovascular risk factor, Am J Med Sci, 330, (2005)
[5] Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Back M., Et al., 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, 42, (2021)
[6] Delabays B., de la Harpe R., Vollenweider P., Fournier S., Muller O., Strambo D., Et al., Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease, Eur J Prev Cardiol, 30, (2023)
[7] Mortensen M.B., Falk E., Primary prevention with statins in the elderly, J Am Coll Cardiol, 71, pp. 85-94, (2018)
[8] McEvoy J.W., Jennings C., Kotseva K., De Bacquer D., De Backer G., Erlund I., Et al., Variation in secondary prevention of coronary heart disease: the INTERASPIRE study, Eur Heart J, 45, (2024)
[9] Verburgt E., Hilkens N.A., Ekker M.S., Schellekens M.M.I., Boot E.M., Immens M.H.M., Et al., Short-term and long-term risk of recurrent vascular event by cause after ischemic stroke in young adults, JAMA Netw Open, 7, (2024)
[10] Song J., Murugiah K., Hu S., Gao Y., Li X., Krumholz H.M., Et al., Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China, Heart, 107, (2020)

← 1 2 3 4 5 →